LabGenius uses Graphcore’s IPUs to speed up drug discovery

AI-driven scientific research firm LabGenius is harnessing the power of Graphcore’s IPUs (Intelligence Processing Units) to speed up its drug discovery efforts.

LabGenius is currently focused on discovering new treatments for cancer and inflammatory diseases. The firm combines AI, lab automation, and synthetic biology for its potentially life-saving work.

Until now, the company has been using traditional GPUs for its workloads. LabGenius reports that switching to...

21 April 2022 | Applications

BenevolentAI’s drug discovery platform identifies novel target for ulcerative colitis

London-based AI pioneer BenevolentAI has identified a novel target for ulcerative colitis through its drug discovery platform.

The candidate was identified by scientists who used BenevolentAI’s target ID tools and machine learning models to identify and experimentally validate a novel biological target. Impressively, the achievement was made without any prior reference in published alliteration or patents linking the gene to ulcerative colitis.

Anne Phelan, Chief...

14 October 2021 | Industries